Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
NCT04819360 · Brigitte Schürch · PHASE4 · terminated · last registry update 2024-09-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of recruitment” | – | Registry record, Brigitte Schürch |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CHRM3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-19Results posted on the registry: AstraZeneca, BGF MDI HFO 320/14.4/9.6 μg + BGF MDI HFA 320/14.4/9.6 μg (NCT05573464)
- 2025-08-22Also stopped (withdrawn): Johns Hopkins University, ibogaine with magnesium treatment + 5-MeO-DMT (NCT06810765)
- 2025-08-15Also stopped (withdrawn): AstraZeneca, Treatment A: BGF MDI HFA + Treatment B: BGF MDI HFO (NCT06340581)
- 2025-06-26Phase 3 first posted: Immunovant Sciences GmbH, IMVT-1402 + IMVT-1402 (NCT07039916)
- 2025-05-28Results posted on the registry: AstraZeneca, Treatment A (BGF MDI HFO with oral activated charcoal) + Treatment B (BGF MDI HFA with oral activated charcoal) (NCT05477108)
- 2025-04-29Results posted on the registry: AstraZeneca, Treatment A: BGF MDI HFO + Treatment B: BGF MDI HFA (NCT05569421)
- 2025-04-08Also stopped (terminated): Colorado State University, Acetylcholine + Sodium Nitroprusside (NCT04001647)
- 2025-02-05Results posted on the registry: Visus Therapeutics, BRIMOCHOL™ + BRIMOCHOL™ F (NCT04774237)
- 2024-12-24Also stopped (withdrawn): Dr. August Wolff GmbH & Co. KG Arzneimittel, WO3970 + Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use (NCT04159610)
- 2024-11-15Also stopped (terminated): Chiesi Farmaceutici S.p.A., Administration via pressurized metered dose inhaler (pMDI) + Administration via pressurized metered dose inhaler (pMDI) (NCT05018598)
- 2024-10-15Phase 3 first posted: Haisco Pharmaceutical Group Co., Ltd., HL231 Solution for Inhalation + Ultibro 110μg/50 μg (NCT06643078)
- 2024-09-23Phase 3 first posted: Alexion Pharmaceuticals, Inc., Gefurulimab (NCT06607627)
- 2024-09-05Results posted on the registry: Visus Therapeutics, BRIMOCHOL™ PF + Carbachol PF (NCT05270863)
- 2024-08-06Results posted on the registry: Johns Hopkins University, [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide) (NCT04055467)
- 2024-06-06Results posted on the registry: Botanix Pharmaceuticals, Sofpironium Bromide Gel, 15% + Vehicle (NCT03836287)
- 2024-05-30Phase 3 first posted: UCB Biopharma SRL, Zilucoplan (NCT06435312)
- 2024-05-21Results posted on the registry: Botanix Pharmaceuticals, Sofpironium Bromide, 15% + Vehicle (NCT03948646)
- 2024-05-07Results posted on the registry: Catalyst Pharmaceuticals, Inc., Amifampridine Phosphate (NCT03579966)
- 2024-05-07Also stopped (terminated): Catalyst Pharmaceuticals, Inc., Amifampridine Phosphate (NCT03579966)
- 2024-04-22Phase 3 first posted: Post Graduate Institute of Medical Education and Research, Chandigarh, Glycopyrronium + Ipratropium (NCT06376942)
- 2024-03-27Also stopped (terminated): GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03446612)
- 2024-03-07Phase 3 first posted: argenx, Efgartigimod IV (NCT06298552)
- 2024-02-28Phase 3 first posted: AstraZeneca, BGF MDI 320/14.4/9.6 μg + GFF MDI 14.4/9.6 μg (NCT06283966)
- 2024-02-16Also stopped (withdrawn): Yale University, Low strength nicotine e-liquid + High strength nicotine e-liquid (NCT04258852)
- 2024-01-31Phase 3 first posted: Eurofarma Laboratorios S.A., Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg + Comparator - Trimbow® (NCT06234345)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision